Chimpanzee adenoviral vectors as vaccines for outbreak pathogens

References

• Moss B, Smith GL, Gerin JL, Purcell RH. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature. 1984;311:67-9. doi:10.1038/311067a0. PMID:6472464
   PubMed Web of Science ®Google Scholar
• Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, Ladell K, Lambe T, Milicic A, Price DA, Hill AV, et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One. 2012;7:e48322. doi:10.1371/journal.pone.0048322. PMID:23118984
   PubMed Web of Science ®Google Scholar
• Bliss CM, Drammeh A, Bowyer G, Sanou GS, Jagne YJ, Ouedraogo O, Edwards NJ, Tarama C, Ouedraogo N, Ouedraogo M, et al. Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. Mol Ther. 2017;25:547-59. doi:10.1016/j.ymthe.2016.11.003. PMID:28153101
   PubMed Web of Science ®Google Scholar
• Sophie Roetynck, Victorine Mensah, Ebrima Kanteh, Georgina Bowyer, Amy Ndaw, Francis Oko, Carly Bliss, Riccardo Cortese, Alfredo Nicosia, Rachel Roberts, et al. Immunogenicity of ChAd63/MVA ME-TRAP malaria vectored vaccines when given with routine childhood vaccines in Gambian infants and neonates: a randomized controlled trial.. Atlanta (GA) USA: American Society of Tropical Medicine and Hygiene; 2016.
   Google Scholar
• Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011;17:1128-31. doi:10.1038/nm.2447. PMID:21857654
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009;7:393-400. doi:10.1038/nrmicro2129. PMID:19369954
   PubMed Web of Science ®Google Scholar
• Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, et al. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA. 2016;315:1610-23. doi:10.1001/jama.2016.4218. PMID:27092831
   PubMed Web of Science ®Google Scholar
• Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15:1156-66. doi:10.1016/S1473-3099(15)00154-1. PMID:26248510
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, Williams AR, Halstead FD, Moretz SE, Miura K, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther. 2011;19:2269-76. doi:10.1038/mt.2011.176. PMID:21862998
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, Halstead FD, Ewer KJ, Mahungu T, Spencer AJ, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012;7:e31208. doi:10.1371/journal.pone.0031208. PMID:22363582
   PubMed Web of Science ®Google Scholar
• de Barra E, Hodgson SH, Ewer KJ, Bliss CM, Hennigan K, Collins A, Berrie E, Lawrie AM, Gilbert SC, Nicosia A, et al. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS One. 2014;9:e115161. doi:10.1371/journal.pone.0115161. PMID:25522180
   PubMed Web of Science ®Google Scholar
• Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, de Barra E, Havelock T, Bowyer G, Poulton ID, et al. Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. J Infect Dis. 2015;211:1076-86. doi:10.1093/infdis/jiu579. PMID:25336730
   PubMed Web of Science ®Google Scholar
• Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med. 2016;374:1635-46. doi:10.1056/NEJMoa1411627. PMID:25629663
   PubMed Web of Science ®Google Scholar
• Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013;4:2836. doi:10.1038/ncomms3836. PMID:24284865
   PubMed Web of Science ®Google Scholar
• McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med. 2004;10:1240-4. doi:10.1038/nm1128. PMID:15502839
   PubMed Web of Science ®Google Scholar
• Lauer KB, Borrow R, Blanchard TJ. Multivalent and Multipathogen Viral Vector Vaccines. Clin Vaccine Immunol. 2017;24. doi:10.1128/CVI.00298-16. PMID:27535837.
   PubMed Web of Science ®Google Scholar
• Dahlke C, Kasonta R, Lunemann S, Krähling V, Zinser ME, Biedenkopf N, Fehling SK, Ly ML, Rechtien A, Stubbe HC, et al. Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. EBioMedicine. 2017;19:107-118. Epub 2017 Apr 5; doi:10.1016/j.ebiom.2017.03.045. PMID:28434944.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389:505-18. doi:10.1016/S0140-6736(16)32621-6. PMID:28017403
   PubMed Web of Science ®Google Scholar
• Mire CE, Geisbert TW, Feldmann H, Marzi A. Ebola virus vaccines – reality or fiction? Expert Rev Vaccines. 2016;15:1421-30. doi:10.1080/14760584.2016.1178068. PMID:27078187
   PubMed Web of Science ®Google Scholar
• Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther. 1998;9:1909-17. doi:10.1089/hum.1998.9.13-1909. PMID:9741429
   PubMed Web of Science ®Google Scholar
• Reddy PS, Ganesh S, Hawkins L, Idamakanti N. Generation of recombinant adenovirus using the Escherichia coli BJ5183 recombination system. Methods Mol Med. 2007;130:61-8. PMID:17401164
   PubMedGoogle Scholar
• Ruzsics Z, Lemnitzer F, Thirion C. Engineering adenovirus genome by bacterial artificial chromosome (BAC) technology. Methods Mol Biol. 2014;1089:143-58. doi:10.1007/978-1-62703-679-5_11. PMID:24132484
   PubMedGoogle Scholar
• Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AV, Cottingham MG. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One. 2012;7:e40385. doi:10.1371/journal.pone.0040385. PMID:22808149
   PubMed Web of Science ®Google Scholar
• Matthews QL. Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm. 2011;8:3-11. doi:10.1021/mp100214b. PMID:21047139
   PubMed Web of Science ®Google Scholar
• Wu L, Zhang Z, Gao H, Li Y, Hou L, Yao H, Wu S, Liu J, Wang L, Zhai Y, et al. Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Hum Vaccin Immunother. 2017;13:1-8. doi:10.1080/21645515.2017.1342021.
   Web of Science ®Google Scholar
• Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011;85:4222-33. doi:10.1128/JVI.02407-10. PMID:21325402
   PubMed Web of Science ®Google Scholar
• Gu L, Icyuz M, Krendelchtchikova V, Krendelchtchikov A, Johnston AE, Matthews QL. Development of an Ad5H3 Chimera Using the “Antigen Capsid-Incorporation” Strategy for an Alternative Vaccination Approach. Open Virol J. 2016;10:10-20. doi:10.2174/1874357901610010010. PMID:27335626
   PubMedGoogle Scholar
• Morris SJ, Sebastian S, Spencer AJ, Gilbert SC. Simian adenoviruses as vaccine vectors. Future Virol. 2016;11:649-59. doi:10.2217/fvl-2016-0070
   PubMed Web of Science ®Google Scholar
• Whitt MA, Geisbert TW, Mire CE. Single-Vector, Single-Injection Recombinant Vesicular Stomatitis Virus Vaccines Against High-Containment Viruses. Methods Mol Biol. 2016;1403:295-311. doi:10.1007/978-1-4939-3387-7_16. PMID:27076138
   PubMedGoogle Scholar
• Aguilar HC, Iorio RM. Henipavirus membrane fusion and viral entry. Curr Top Microbiol Immunol. 2012;359:79-94. PMID:22427111
   PubMed Web of Science ®Google Scholar
• Owens RJ, Rose JK. Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus. J Virol. 1993;67:360-5. PMID:8093220
   PubMed Web of Science ®Google Scholar
• van den Pol AN, Dalton KP, Rose JK. Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol. 2002;76:1309-27. doi:10.1128/JVI.76.3.1309-1327.2002. PMID:11773406
   PubMed Web of Science ®Google Scholar
• Clarke DK, Nasar F, Chong S, Johnson JE, Coleman JW, Lee M, Witko SE, Kotash CS, Abdullah R, Megati S, et al. Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates. J Virol. 2014;88:6690-701. doi:10.1128/JVI.03441-13. PMID:24696472
   PubMed Web of Science ®Google Scholar
• Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD, et al. First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090). Open Forum Infect Dis. 2015;2:ofv082. PMID:26199949
   PubMed Web of Science ®Google Scholar
• Yang TC, Dayball K, Wan YH, Bramson J. Detailed analysis of the CD8+ T-cell response following adenovirus vaccination. J Virol. 2003;77:13407-11. doi:10.1128/JVI.77.24.13407-13411.2003. PMID:14645597
   PubMed Web of Science ®Google Scholar
• Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013;13:421-33. doi:10.2174/1566523213666131125095046. PMID:24279313
   PubMed Web of Science ®Google Scholar
• Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003;77:8263-71. doi:10.1128/JVI.77.15.8263-8271.2003. PMID:12857895
   PubMed Web of Science ®Google Scholar
• Ausubel LJ, Meseck M, Derecho I, Lopez P, Knoblauch C, McMahon R, Anderson J, Dunphy N, Quezada V, Khan R, et al. Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment. Hum Gene Ther. 2011;22:489-97. doi:10.1089/hum.2010.159. PMID:21083425
   PubMed Web of Science ®Google Scholar
• Arnemo M, Viksmoen Watle SS, Schoultz KM, Vainio K, Norheim G, Moorthy V, Fast P, Røttingen JA, Gjøen T. Stability of a Vesicular Stomatitis Virus-Vectored Ebola Vaccine. J Infect Dis. 2016;213:930-3. doi:10.1093/infdis/jiv532. PMID:26563239
   PubMed Web of Science ®Google Scholar
• Pelliccia M, Andreozzi P, Paulose J, D'Alicarnasso M, Cagno V, Donalisio M, Civra A, Broeckel RM, Haese N, Jacob Silva P, et al. Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months. Nat Commun. 2016;7:13520. doi:10.1038/ncomms13520. PMID:27901019
   PubMed Web of Science ®Google Scholar
• Dulal P, Wright D, Ashfield R, Hill AV, Charleston B, Warimwe GM. Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle. Vaccine. 2016;34:2296-8. doi:10.1016/j.vaccine.2016.03.061. PMID:27020712
   PubMed Web of Science ®Google Scholar
• O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, Goodman AL, Edwards NJ, Reyes-Sandoval A, Bird P, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. The Journal of infectious diseases. 2012;205:772-81. doi:10.1093/infdis/jir850. PMID:22275401
   PubMed Web of Science ®Google Scholar
• van Doremalen N, Munster VJ. Animal models of Middle East respiratory syndrome coronavirus infection. Antiviral Res. 2015;122:28-38. doi:10.1016/j.antiviral.2015.07.005. PMID:26192750
   PubMed Web of Science ®Google Scholar
• Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, Smee DF, Barnard DL. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 2009;395:210-22. doi:10.1016/j.virol.2009.09.023. PMID:19853271
   PubMed Web of Science ®Google Scholar
• Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, Gale MJ Jr, Baric RS, Enjuanes L, Gallagher T, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A. 2014;111:4970-5. doi:10.1073/pnas.1323279111. PMID:24599590
   PubMed Web of Science ®Google Scholar
• Holbein ME, Berglund JP, Weatherwax K, Gerber DE, Adamo JE. Access to Investigational Drugs: FDA Expanded Access Programs or “Right-to-Try” Legislation? Clin Transl Sci. 2015;8:526-32. doi:10.1111/cts.12255. PMID:25588691
   PubMed Web of Science ®Google Scholar
• WHO. Blueprint for R&D preparedness and response to public health emergencies due to highly infectious pathogens.. Geneva: WHO,. 2015:7.
   Google Scholar
• Serdobova I, Kieny MP. Assembling a global vaccine development pipeline for infectious diseases in the developing world. Am J Public Health. 2006;96:1554-9. doi:10.2105/AJPH.2005.074583. PMID:16873743
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Mahmoud AA, Farrar J. Establishing a Global Vaccine-Development Fund. N Engl J Med. 2015;373:297-300. doi:10.1056/NEJMp1506820. PMID:26200974
   PubMed Web of Science ®Google Scholar
• Butler D. Billion-dollar project aims to prep vaccines before epidemics hit. Nature.. Vol. 541: Springer Nature, 2017:444-5. doi:10.1038/nature.2017.21329
   Google Scholar
• Andre FE. How the research-based industry approaches vaccine development and establishes priorities. Dev Biol (Basel). 2002;110:25-9. PMID:12477303
   PubMedGoogle Scholar
• Diehl WE, Lin AE, Grubaugh ND, Carvalho LM, Kim K, Kyawe PP, McCauley SM, Donnard E, Kucukural A, McDonel P, et al. Ebola Virus Glycoprotein with Increased Infectivity Dominated the. 2013–2016 Epidemic. Cell. 2016;167:1088-98 e6. doi:10.1016/j.cell.2016.10.014. PMID:27814506
   PubMed Web of Science ®Google Scholar
• Urbanowicz RA, McClure CP, Sakuntabhai A, Sall AA, Kobinger G, Müller MA, Holmes EC, Rey FA, Simon-Loriere E, Ball JK. Human Adaptation of Ebola Virus during the West African Outbreak. Cell. 2016;167:1079-87 e5. doi:10.1016/j.cell.2016.10.013. PMID:27814505
   PubMed Web of Science ®Google Scholar
• WHO. Nipah virus outbreaks in the WHO South-East Asia Region. Available at: http://www.searo.who.int/entity/emerging_diseases/links/nipah_virus_outbreaks_sear/en/. Accessed February 10. 2017.
   Google Scholar
• Clayton BA. Nipah virus: transmission of a zoonotic paramyxovirus. Curr Opin Virol. 2017;22:97-104. doi:10.1016/j.coviro.2016.12.003. PMID:28088124
   PubMed Web of Science ®Google Scholar
• Broder CC, Weir DL, Reid PA. Hendra virus and Nipah virus animal vaccines. Vaccine. 2016;34:3525-34. doi:10.1016/j.vaccine.2016.03.075. PMID:27154393
   PubMed Web of Science ®Google Scholar
• ANZCTR. A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Various Dosing Regimens of Intravenous anti-Hendra Virus Antibody (mAb m102.4) in Healthy Subjects. Available at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368110&isReview=true. Accessed 10th February. 2017.
   Google Scholar
• Wong KT, Grosjean I, Brisson C, Blanquier B, Fevre-Montange M, Bernard A, Loth P, Georges-Courbot MC, Chevallier M, Akaoka H, et al. A golden hamster model for human acute Nipah virus infection. Am J Pathol. 2003;163:2127-37. doi:10.1016/S0002-9440(10)63569-9. PMID:14578210
   PubMed Web of Science ®Google Scholar
• Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern JA, Green D, Hancock TJ, Chan YP, et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog. 2009;5:e1000642. doi:10.1371/journal.ppat.1000642. PMID:19888339
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-DiCaprio KM, Hickey AC, Smith MA, Chan YP, Wang LF, Mattapallil JJ, Geisbert JB, Bossart KN, Broder CC. Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One. 2010;5:e10690. doi:10.1371/journal.pone.0010690. PMID:20502528
   PubMed Web of Science ®Google Scholar
• DeBuysscher BL, Scott D, Marzi A, Prescott J, Feldmann H. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine. 2014;32:2637-44. doi:10.1016/j.vaccine.2014.02.087. PMID:24631094
   PubMed Web of Science ®Google Scholar
• Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, LaCasse R, Geisbert JB, Feng YR, Chan YP, Hickey AC, et al. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med. 2012;4:146ra07. doi:10.1126/scitranslmed.3004241
   Web of Science ®Google Scholar
• Pallister J, Middleton D, Wang LF, Klein R, Haining J, Robinson R, Yamada M, White J, Payne J, Feng YR, et al. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine. 2011;29:5623-30. doi:10.1016/j.vaccine.2011.06.015. PMID:21689706
   PubMed Web of Science ®Google Scholar
• Broder CC, Xu K, Nikolov DB, Zhu Z, Dimitrov DS, Middleton D, Pallister J, Geisbert TW, Bossart KN, Wang LF. A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral Res. 2013;100:8-13. doi:10.1016/j.antiviral.2013.06.012. PMID:23838047
   PubMed Web of Science ®Google Scholar
• Satterfield BA, Dawes BE, Milligan GN. Status of vaccine research and development of vaccines for Nipah virus. Vaccine. 2016;34:2971-5. doi:10.1016/j.vaccine.2015.12.075. PMID:26973068
   PubMed Web of Science ®Google Scholar
• Fisher-Hoch SP, Tomori O, Nasidi A, Perez-Oronoz GI, Fakile Y, Hutwagner L, McCormick JB. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ. 1995;311:857-9. doi:10.1136/bmj.311.7009.857. PMID:7580496
   PubMed Web of Science ®Google Scholar
• McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis. 1987;155:437-44. doi:10.1093/infdis/155.3.437. PMID:3805771
   PubMed Web of Science ®Google Scholar
• McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986;314:20-6.
   PubMed Web of Science ®Google Scholar
• Mylne AQ, Pigott DM, Longbottom J, Shearer F, Duda KA, Messina JP, Weiss DJ, Moyes CL, Golding N, Hay SI. Mapping the zoonotic niche of Lassa fever in Africa. Trans R Soc Trop Med Hyg. 2015;109:483-92. doi:10.1093/trstmh/trv047. PMID:26085474
   PubMed Web of Science ®Google Scholar
• Sogoba N, Feldmann H, Safronetz D. Lassa fever in West Africa: evidence for an expanded region of endemicity. Zoonoses Public Health. 2012;59 Suppl 2:43-7. doi:10.1111/j.1863-2378.2012.01469.x. PMID:22958249
   PubMed Web of Science ®Google Scholar
• Ambrosio A, Saavedra M, Mariani M, Gamboa G, Maiza A. Argentine hemorrhagic fever vaccines. Hum Vaccin. 2011;7:694-700. doi:10.4161/hv.7.6.15198. PMID:21451263
   PubMed Web of Science ®Google Scholar
• Mahanty S, Bausch DG, Thomas RL, Goba A, Bah A, Peters CJ, Rollin PE. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J Infect Dis. 2001;183:1713-21. doi:10.1086/320722. PMID:11372023
   PubMed Web of Science ®Google Scholar
• ?A3B2 tlsb=-0.15pt?>Russier M, Pannetier D, Baize S. Immune responses and Lassa virus infection. Viruses. 2012;4:2766-85. doi:10.3390/v4112766. PMID:23202504
   PubMedGoogle Scholar
• Prescott JB, Marzi A, Safronetz D, Robertson SJ, Feldmann H, Best SM. Immunobiology of Ebola and Lassa virus infections. Nat Rev Immunol. 2017. doi:10.1038/nri.2016.138. PMID:28111475
   PubMed Web of Science ®Google Scholar
• McCormick JB, Mitchell SW, Kiley MP, Ruo S, Fisher-Hoch SP. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J Med Virol. 1992;37:1-7. doi:10.1002/jmv.1890370102. PMID:1619397
   PubMed Web of Science ®Google Scholar
• Auperin DD, Esposito JJ, Lange JV, Bauer SP, Knight J, Sasso DR, McCormick JB. Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res. 1988;9:233-48. doi:10.1016/0168-1702(88)90033-0. PMID:3354260
   PubMed Web of Science ®Google Scholar
• Clegg JC, Lloyd G. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet. 1987;2:186-8. doi:10.1016/S0140-6736(87)90767-7. PMID:2885642
   PubMed Web of Science ®Google Scholar
• Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Möller P, Wagner R, Volchkov V, Klenk HD, Feldmann H, Ströher U. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78:5458-65. doi:10.1128/JVI.78.10.5458-5465.2004. PMID:15113924
   PubMed Web of Science ®Google Scholar
• Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, Zapata J, Brasky K, Geiger R, Hubbard GB, Bryant J, et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol. 2005;79:13934-42. doi:10.1128/JVI.79.22.13934-13942.2005. PMID:16254329
   PubMed Web of Science ®Google Scholar
• Jiang X, Dalebout TJ, Bredenbeek PJ, Carrion R Jr, Brasky K, Patterson J, Goicochea M, Bryant J, Salvato MS, Lukashevich IS. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine. 2011;29:1248-57. doi:10.1016/j.vaccine.2010.11.079. PMID:21145373
   PubMed Web of Science ®Google Scholar
• Jahrling PB, Smith S, Hesse RA, Rhoderick JB. Pathogenesis of Lassa virus infection in guinea pigs. Infect Immun. 1982;37:771-8. PMID:6749685
   PubMed Web of Science ®Google Scholar
• Walker DH, Wulff H, Lange JV, Murphy FA. Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull World Health Organ. 1975;52:523-34. PMID:821625
   PubMed Web of Science ®Google Scholar
• Carrion R, Jr., Brasky K, Mansfield K, Johnson C, Gonzales M, Ticer A, Lukashevich I, Tardif S, Patterson J. Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol. 2007;81:6482-90. doi:10.1128/JVI.02876-06. PMID:17409137
   PubMed Web of Science ®Google Scholar
• Bredenbeek PJ, Molenkamp R, Spaan WJ, Deubel V, Marianneau P, Salvato MS, Moshkoff D, Zapata J, Tikhonov I, Patterson J, et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology. 2006;345:299-304. doi:10.1016/j.virol.2005.12.001. PMID:16412488
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, Grolla A, Ströher U, Fernando L, Daddario KM, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005;2:e183. doi:10.1371/journal.pmed.0020183. PMID:15971954
   PubMed Web of Science ®Google Scholar
• Falzarano D, Feldmann H. Vaccines for viral hemorrhagic fevers–progress and shortcomings. Curr Opin Virol. 2013;3:343-51. doi:10.1016/j.coviro.2013.04.007. PMID:23773330
   PubMed Web of Science ®Google Scholar
• Lukashevich IS. Advanced vaccine candidates for Lassa fever. Viruses. 2012;4:2514-57. doi:10.3390/v4112514. PMID:23202493
   PubMed Web of Science ®Google Scholar
• Zapata JC, Poonia B, Bryant J, Davis H, Ateh E, George L, Crasta O, Zhang Y, Slezak T, Jaing C, et al. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virol J. 2013;10:52. doi:10.1186/1743-422X-10-52. PMID:23402317
   PubMed Web of Science ®Google Scholar
• Pushko P, Geisbert J, Parker M, Jahrling P, Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol. 2001;75:11677-85. doi:10.1128/JVI.75.23.11677-11685.2001. PMID:11689649
   PubMed Web of Science ®Google Scholar
• Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB. Effective vaccine for lassa fever. J Virol. 2000;74:6777-83. doi:10.1128/JVI.74.15.6777-6783.2000. PMID:10888616
   PubMed Web of Science ®Google Scholar
• Olschlager S, Flatz L. Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials. PLoS Pathog. 2013;9:e1003212. doi:10.1371/journal.ppat.1003212. PMID:23592977
   PubMed Web of Science ®Google Scholar
• Cherry JD. The chronology of the. 2002–2003 SARS mini pandemic. Paediatr Respir Rev. 2004;5:262-9. doi:10.1016/j.prrv.2004.07.009. PMID:15531249
   PubMedGoogle Scholar
• Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953-66. doi:10.1056/NEJMoa030781. PMID:12690092
   PubMed Web of Science ®Google Scholar
• Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302:276-8. doi:10.1126/science.1087139. PMID:12958366
   PubMed Web of Science ®Google Scholar
• Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005;310:676-9. doi:10.1126/science.1118391. PMID:16195424
   PubMed Web of Science ®Google Scholar
• Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814-20. doi:10.1056/NEJMoa1211721. PMID:23075143
   PubMed Web of Science ®Google Scholar
• WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia. Available at: http://www.who.int/csr/don/26-january-2017-mers-saudi-arabia/en/. Accessed February 10. 2017.
   Google Scholar
• Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nature reviews Microbiology. 2013;11:836-48. doi:10.1038/nrmicro3143. PMID:24217413
   PubMed Web of Science ®Google Scholar
• Choi J, Kim MG, Oh YK, Kim YB. Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review. Expert Opin Ther Pat. 2017;27:1-11.
   Web of Science ®Google Scholar
• Excler JL, Delvecchio CJ, Wiley RE, Williams M, Yoon I-K, Modjarrad K, Boujelal M, Moorthy VS, Hersi AS, Kim JH. Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015. Emerg Infect Dis. 2016;22(8). doi:10.3201/eid2208.160229.
   PubMed Web of Science ®Google Scholar
• Agrawal AS, Garron T, Tao X, Peng BH, Wakamiya M, Chan TS, Couch RB, Tseng CT. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol. 2015;89:3659-70. doi:10.1128/JVI.03427-14. PMID:25589660
   PubMed Web of Science ®Google Scholar
• Cockrell AS, Peck KM, Yount BL, Agnihothram SS, Scobey T, Curnes NR, Baric RS, Heise MT. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J Virol. 2014;88:5195-9. doi:10.1128/JVI.03764-13. PMID:24574399
   PubMed Web of Science ®Google Scholar
• Falzarano D, de Wit E, Feldmann F, Rasmussen AL, Okumura A, Peng X, Thomas MJ, van Doremalen N, Haddock E, Nagy L, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 2014;10:e1004250. doi:10.1371/journal.ppat.1004250. PMID:25144235
   PubMed Web of Science ®Google Scholar
• Munster VJ, de Wit E, Feldmann H. Pneumonia from human coronavirus in a macaque model. N Engl J Med. 2013;368:1560-2. doi:10.1056/NEJMc1215691. PMID:23550601
   PubMed Web of Science ®Google Scholar
• Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712. doi:10.1038/ncomms8712. PMID:26218507
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. NCT02670187. Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers. Available at: https://clinicaltrials.gov/ct2/show/NCT02670187?term=NCT02670187&rank=1. Accessed 10th May. 2017.
   Google Scholar
• WHO. Ebola Situation Report- 5th June. 2017. Ebola Situation Report- 5th June. 2017, 2017:1-6 .
   Google Scholar
• Cohen J. As Ebola outbreak grows, question of using vaccine becomes more urgent. Science. 2017.
   Google Scholar
• Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dorrell L. Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol. 2016;41:47-54. doi:10.1016/j.coi.2016.05.014. PMID:27286566
   PubMed Web of Science ®Google Scholar
• King DA, Peckham C, Waage JK, Brownlie J, Woolhouse ME. Epidemiology. Infectious diseases: preparing for the future. Science. 2006;313:1392-3.
   PubMed Web of Science ®Google Scholar
• Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. Global trends in emerging infectious diseases. Nature. 2008;451:990-3. doi:10.1038/nature06536. PMID:18288193
   PubMed Web of Science ®Google Scholar
• Butler D. How to beat the next Ebola. Nature. 2015;524:22-5. doi:10.1038/524022a. PMID:26245563
   PubMed Web of Science ®Google Scholar
• Walther M, Thompson FM, Dunachie S, Keating S, Todryk S, Berthoud T, Andrews L, Andersen RF, Moore A, Gilbert SC, et al. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun. 2006;74:2706-16. doi:10.1128/IAI.74.5.2706-2716.2006. PMID:16622207
   PubMed Web of Science ®Google Scholar
• McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med. 2003;9:729-35. doi:10.1038/nm881. PMID:12766765
   PubMed Web of Science ®Google Scholar
• Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A. 2005;102:4836-41. doi:10.1073/pnas.0406381102. PMID:15781866
   PubMed Web of Science ®Google Scholar
• Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, Todryk S, Keating S, Lang T, Lowe B, Gikonyo C, et al. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials. 2006;1:e29. PMID:17053830
   PubMedGoogle Scholar
• Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, Bliss C, Hodgson SH, Njuguna P, Viebig NK, et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med. 2015;7:286re5.
   PubMed Web of Science ®Google Scholar
• Rampling T, Ewer K, Bowyer G, Venkatraman N, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine – Preliminary Report. N Engl J Med. 2015;372(5):1-10. PMID:25629663.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, Hu YM, Meng FY, Xu JJ, Tang R, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2015;385:2272-9. PMID:25817373
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe – Preliminary Report. N Engl J Med. 2016;374(17):1647-60. Epub 2015 Apr 1. doi:10.1056/NEJMoa1502924.
   Web of Science ®Google Scholar
• Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31-42. PMID:26546548
   PubMed Web of Science ®Google Scholar
• Nakayama E, Saijo M. Animal models for Ebola and Marburg virus infections. Frontiers in microbiology. 2013;4:267. PMID:24046765
   PubMed Web of Science ®Google Scholar
• Yun NE, Seregin AV, Walker DH, Popov VL, Walker AG, Smith JN, Miller M, de la Torre JC, Smith JK, Borisevich V, et al. Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus. J Virol. 2013;87:10908-11. PMID:23903830
   PubMed Web of Science ®Google Scholar
• Dhondt KP, Mathieu C, Chalons M, Reynaud JM, Vallve A, Raoul H, Horvat B. Type I interferon signaling protects mice from lethal henipavirus infection. J Infect Dis. 2013;207:142-51. PMID:23089589
   PubMed Web of Science ®Google Scholar
• Bente DA, Alimonti JB, Shieh WJ, Camus G, Ströher U, Zaki S, Jones SM. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol. 2010;84:11089-100. doi:10.1128/JVI.01383-10. PMID:20739514
   PubMed Web of Science ®Google Scholar
• Lazear HM, Govero J, Smith AM, Platt DJ, Fernandez E, Miner JJ, Diamond MS. A Mouse Model of Zika Virus Pathogenesis. Cell Host Microbe. 2016;19:720-30. doi:10.1016/j.chom.2016.03.010. PMID:27066744
   PubMed Web of Science ®Google Scholar
• Couderc T, Chretien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I, et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog. 2008;4:e29. doi:10.1371/journal.ppat.0040029. PMID:18282093
   PubMed Web of Science ®Google Scholar
• Liu Q, He B, Huang SY, Wei F, Zhu XQ. Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis. Lancet Infect Dis. 2014;14:763-72. doi:10.1016/S1473-3099(14)70718-2. PMID:24837566
   PubMed Web of Science ®Google Scholar